Altunan, BenguUnal, AysunEfendi, HusnuKoseoglu, MesrureTerzi, MuratKotan, DilcanTamam, Yusuf2024-06-122024-06-1220232211-03482211-0356https://doi.org/10.1016/j.msard.2023.104880https://hdl.handle.net/20.500.14551/21143Background: Follow-on disease modifying therapies (FO-DMTs) do not always require Phase III studies. There are concerns that cheaper FO-DMTs are only used to reduce healthcare costs. However, the well-being of people with MS (pwMS) should be a priority. We aimed to evaluate the efficacy, safety and treatment satisfaction of one of the FO-Fingolimod (FTY) used in Turkey with the approval of Turkish Ministry of Health.Methods: PwMS under FTY were recruited from 13 centers and real-world data and answers of satisfaction and adherence statements of pwMS on FTY treatment were analyzed.Results: Data of 239 pwMS were obtained. The duration of FTY treatment was 2.5 & PLUSMN; 0.8 (1-4) years in pwMS who were included in the study and whose treatment continued for at least one year. Significant decreases in annual relapse rate (p < 0.001), Expanded Disability Status Scale (p < 0.001) and neuroimaging findings (p < 0.001) were observed. While 64% of the patients were satisfied and 71.5% were found to adherent with this FO-FTY.Conclusion: This multicenter retrospective study found that the efficacy, safety and treatment adherence of a prescribed FO-FTY were consistent with the results of real-world studies. Studies including real-world data may provide guidance to address issues related to FO-FTY use.en10.1016/j.msard.2023.104880info:eu-repo/semantics/closedAccessFollow-On DrugGeneric FingolimodReal-World DataEfficacySafetySatisfactionAdherenceOral FingolimodMulticenterEfficacyQualitySafetyArticle77N/AWOS:0010397584000012-s2.0-8516525104637459716Q1